Chaperone-dependent E3 Ubiquitin Ligase CHIP Mediates a Degradative Pathway for C-ErbB2/Neu

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2002 Sep 20

PMID 12239347

Citations 216

Authors

Wanping Xu

Monica Marcu

Xitong Yuan

Edward Mimnaugh

Cam Patterson

Len Neckers

Affiliations

Soon will be listed here.

Abstract

Overexpression of the transmembrane receptor tyrosine kinase ErbB2 is common in multiple malignancies, including breast and ovarian cancer. ErbB2 is resistant to degradation mediated by c-Cbl, the E3 ubiquitin ligase responsible for ligand-induced ubiquitination of ErbB1 (epidermal growth factor receptor). Because of its resistance to degradation, ErbB2 is the preferred dimerization partner for other members of the ErbB family, and its overexpression in vivo is associated with poor prognosis. We now show that the chaperone-binding ubiquitin ligase CHIP efficiently ubiquitinates and down-regulates ErbB2. CHIP expression shortens the half-life of both nascent and mature ErbB2 protein. In vitro ubiquitination assay shows that CHIP serves as a ubiquitin ligase for ErbB2, and both exogenously expressed and endogenous CHIP coprecipitate with the kinase. Furthermore, CHIP association with ErbB2 requires a chaperone intermediate and is increased by the chaperone-binding drug geldanamycin, a potent stimulator of ErbB2 ubiquitination and degradation. These data describe a previously unrecognized pathway, amenable to pharmacologic manipulation, that mediates ErbB2 stability.

Citing Articles

Phosphorylation-State Modulated Binding of HSP70: Structural Insights and Compensatory Protein Engineering.

Stewart M, Paththamperuma C, McCann C, Cottingim K, Zhang H, DelVecchio R bioRxiv. 2025; .

PMID: 40027613 PMC: 11870554. DOI: 10.1101/2025.02.17.637997.

CHIP drives proteasomal degradation of NUR77 to alleviate oxidative stress and intrinsic apoptosis in cisplatin-induced nephropathy.

Zhang H, Deng Z, Wang Y, Zheng X, Zhou L, Yan S Commun Biol. 2024; 7(1):1403.

PMID: 39462094 PMC: 11513124. DOI: 10.1038/s42003-024-07118-0.

Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy.

Abdullah O, Omran Z Int J Mol Sci. 2024; 25(20).

PMID: 39457075 PMC: 11509085. DOI: 10.3390/ijms252011293.

CHIP ameliorates nonalcoholic fatty liver disease via promoting K63- and K27-linked STX17 ubiquitination to facilitate autophagosome-lysosome fusion.

Rho H, Kim S, Kim S, Kim J, Lee S, Park S Nat Commun. 2024; 15(1):8519.

PMID: 39353976 PMC: 11445385. DOI: 10.1038/s41467-024-53002-0.

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.

Xu P, Yang J, Chen B, Ning S, Zhang X, Wang L Nat Commun. 2024; 15(1):6626.

PMID: 39103353 PMC: 11300456. DOI: 10.1038/s41467-024-50459-x.

References

Klapper L, Kirschbaum M, Sela M, Yarden Y . Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 1999; 77:25-79. View

Joazeiro C, Wing S, Huang H, Leverson J, Hunter T, Liu Y . The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999; 286(5438):309-12. DOI: 10.1126/science.286.5438.309. View

Klapper L, Waterman H, Sela M, Yarden Y . Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000; 60(13):3384-8. View

An W, Schulte T, Neckers L . The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000; 11(7):355-60. View

MEACHAM G, Patterson C, Zhang W, Younger J, Cyr D . The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol. 2001; 3(1):100-5. DOI: 10.1038/35050509. View

Connell P, Ballinger C, Jiang J, Wu Y, Thompson L, Hohfeld J . The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol. 2001; 3(1):93-6. DOI: 10.1038/35050618. View

Ouyang X, Gulliford T, Zhang H, Smith G, Huang G, Epstein R . Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer. Mol Cell Biochem. 2001; 218(1-2):47-54. DOI: 10.1023/a:1007249004222. View

Xu W, Mimnaugh E, Rosser M, Nicchitta C, Marcu M, Yarden Y . Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem. 2000; 276(5):3702-8. DOI: 10.1074/jbc.M006864200. View

Mendelsohn J, Baselga J . The EGF receptor family as targets for cancer therapy. Oncogene. 2001; 19(56):6550-65. DOI: 10.1038/sj.onc.1204082. View

10.

de Melker A, Van Der Horst G, Calafat J, Jansen H, Borst J . c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci. 2001; 114(Pt 11):2167-78. DOI: 10.1242/jcs.114.11.2167. View

11.

Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama K . U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem. 2001; 276(35):33111-20. DOI: 10.1074/jbc.M102755200. View

12.

Kuter I . Breast cancer. Oncologist. 2001; 6(4):338-46. DOI: 10.1634/theoncologist.6-4-338. View

13.

Demand J, Alberti S, Patterson C, Hohfeld J . Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol. 2001; 11(20):1569-77. DOI: 10.1016/s0960-9822(01)00487-0. View

14.

Jiang J, Ballinger C, Wu Y, Dai Q, Cyr D, Hohfeld J . CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem. 2001; 276(46):42938-44. DOI: 10.1074/jbc.M101968200. View

15.

Murata S, Minami Y, Minami M, Chiba T, Tanaka K . CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2001; 2(12):1133-8. PMC: 1084164. DOI: 10.1093/embo-reports/kve246. View

16.

Xu W, Mimnaugh E, Kim J, Trepel J, Neckers L . Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones. 2002; 7(1):91-6. PMC: 514806. DOI: 10.1379/1466-1268(2002)007<0091:hngrti>2.0.co;2. View

17.

Isaacs J, Jung Y, Mimnaugh E, Martinez A, Cuttitta F, Neckers L . Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002; 277(33):29936-44. DOI: 10.1074/jbc.M204733200. View

18.

Lemoine N, Staddon S, Dickson C, Barnes D, Gullick W . Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene. 1990; 5(2):237-9. View

19.

Miller P, Diorio C, Moyer M, Schnur R, Bruskin A, Cullen W . Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res. 1994; 54(10):2724-30. View

20.

Johnson J, Toft D . Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol. 1995; 9(6):670-8. DOI: 10.1210/mend.9.6.8592513. View